324 related articles for article (PubMed ID: 37395750)
1. Targeting Ras with protein engineering.
Tomazini A; Shifman JM
Oncotarget; 2023 Jul; 14():672-687. PubMed ID: 37395750
[TBL] [Abstract][Full Text] [Related]
2. Ras proteins as therapeutic targets.
Chakraborty A; Linnane E; Ross S
Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
[TBL] [Abstract][Full Text] [Related]
3. Improving Prospects for Targeting RAS.
Singh H; Longo DL; Chabner BA
J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
[TBL] [Abstract][Full Text] [Related]
4. Engineered variants of the Ras effector protein RASSF5 (NORE1A) promote anticancer activities in lung adenocarcinoma.
Singh A; Erijman A; Noronha A; Kumar H; Peleg Y; Yarden Y; Shifman JM
J Biol Chem; 2021 Dec; 297(6):101353. PubMed ID: 34717958
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
6. Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.
Shin SM; Choi DK; Jung K; Bae J; Kim JS; Park SW; Song KH; Kim YS
Nat Commun; 2017 May; 8():15090. PubMed ID: 28489072
[TBL] [Abstract][Full Text] [Related]
7. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
8. Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S).
Zhang Z; Guiley KZ; Shokat KM
Nat Chem Biol; 2022 Nov; 18(11):1177-1183. PubMed ID: 35864332
[TBL] [Abstract][Full Text] [Related]
9. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
Tang D; Kroemer G; Kang R
Mol Cancer; 2021 Oct; 20(1):128. PubMed ID: 34607583
[TBL] [Abstract][Full Text] [Related]
11. NMR in integrated biophysical drug discovery for RAS: past, present, and future.
Marshall CB; KleinJan F; Gebregiworgis T; Lee KY; Fang Z; Eves BJ; Liu NF; Gasmi-Seabrook GMC; Enomoto M; Ikura M
J Biomol NMR; 2020 Nov; 74(10-11):531-554. PubMed ID: 32804298
[TBL] [Abstract][Full Text] [Related]
12. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
Nyíri K; Koppány G; Vértessy BG
Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
[TBL] [Abstract][Full Text] [Related]
13. Identification of Potential Inhibitors Targeting GTPase-Kirsten RAt Sarcoma Virus (K-Ras) Driven Cancers via E-Pharmacophore-Based Virtual Screening and Drug Repurposing Approach.
Kumar S U; Varghese RP; Preethi VA; Doss CGP; Zayed H
Front Biosci (Landmark Ed); 2023 Nov; 28(11):288. PubMed ID: 38062837
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.
Wang A; Liu J; Li X; Zou F; Qi Z; Qi S; Liu Q; Wang Z; Cao J; Jiang Z; Wang B; Ge J; Wang L; Wang W; Liu J; Liu Q
Eur J Pharmacol; 2023 Aug; 952():175752. PubMed ID: 37164118
[TBL] [Abstract][Full Text] [Related]
15. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M; Novello S; Passiglia F
Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
[TBL] [Abstract][Full Text] [Related]
16. Progress in targeting RAS with small molecule drugs.
McCormick F
Biochem J; 2019 Jan; 476(2):365-374. PubMed ID: 30705085
[TBL] [Abstract][Full Text] [Related]
17. Targeting Ras with Macromolecules.
Pei D; Chen K; Liao H
Cold Spring Harb Perspect Med; 2018 Mar; 8(3):. PubMed ID: 28778966
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket.
Wallon L; Khan I; Teng KW; Koide A; Zuberi M; Li J; Ketavarapu G; Traaseth NJ; O'Bryan JP; Koide S
Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2204481119. PubMed ID: 36252024
[TBL] [Abstract][Full Text] [Related]
19. Drugging K-Ras
Ni D; Li X; He X; Zhang H; Zhang J; Lu S
Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
[TBL] [Abstract][Full Text] [Related]
20. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]